​​Cersci Therapeutics

Dallas, United States Founded: 2015 • Age: 11 yrs Acquired By Acadia Pharma
Non-opioid therapeutics for acute and chronic pain treatment are developed.

About ​​Cersci Therapeutics

​​Cersci Therapeutics is a Healthcare company based in Dallas (United States) founded in 2015, and was acquired by Acadia Pharma in August 2020. Non-opioid therapeutics for acute and chronic pain treatment are developed. ​​Cersci Therapeutics has raised $12 million across 4 funding rounds from investors including HHS and Acadia. ​​Cersci Therapeutics offers products and services including SMARThatch. Its focus areas include Life Sciences, Neurology, Drugs and Pain. Its legal entity is CiDRA Concrete Systems Inc. Its competitors include Flexion Therapeutics, Eliem Therapeutics and Zogenix; 3 of its 3 listed competitors have raised funding.

Company details

Cersci Therapeutics was founded in 2015 in Dallas, United States, within the biotechnology sector. Focus is placed on non-opioid therapeutics targeting acute and chronic pain through AMPK activators and peroxynitrite scavengers. Operations involve advancing these compounds toward an Investigational New Drug application with the FDA. Technology is safeguarded by issued and pending patents, with current efforts directed toward fundraising.

  • Headquarters Dallas, United States
  • Stage Acquired
  • Sectors
    Healthcare
  • Website cersci.com
  • Social LinkedIn X
  • Acquired by Acadia Pharma (Aug 2020)
  • Legal Name Cidra Concrete Systems Inc.
Key Metrics
  • Total Equity Funding
    $12M (USD)

    in 4 rounds

  • Latest Funding Round
    $12M (USD), Series A

    Mar 2020

  • Investors
    HHS

    & 1 more

  • Acquired by
    Acadia Pharma

    (Aug 2020)

Products & Services of ​​Cersci Therapeutics

​​Cersci Therapeutics offers a comprehensive portfolio of products and services, including SMARThatch.

SMARThatch
Measurement System

Real-time monitoring of concrete truck parameters for quality control

Funding Insights of ​​Cersci Therapeutics

​​Cersci Therapeutics has successfully raised a total of $12M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $12 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $12M
  • Total Rounds 4
  • Last Round Series A — $12M
  • First Round $225,000

    (Feb 2017)

  • Investors Count 1

All 4 funding rounds of Cersci Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2020$12MSeries A––
–
Aug 2018$221,823Grant––
Aug 2017$1.73MGrant––
Feb 2017$225,000Grant––
Valuation history

2 investors in total: 2 institutional.

Investors in ​​Cersci Therapeutics

​​Cersci Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Acadia.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Public health and human services are overseen by HHS.
1953hhs.gov
Acadia Pharmaceuticals is focused on developing therapies for neurological disorders.
acadia-pharm.comSan Diego, United States
Premium access

Investor details for Cersci Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of ​​Cersci Therapeutics

4 dated milestones of ​​Cersci Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.

  1. Founded ​​Cersci Therapeutics is founded.
  2. Funding First funding round of $225K.
  3. Funding Latest funding round, Series A, of $12.0M.
  4. Exit Acquired by Acadia Pharma.

Competitors of ​​Cersci Therapeutics

​​Cersci Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Eliem Therapeutics and Zogenix.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
flexiontherapeutics.com2007Woburn, United States$62M692
Developer of therapies for the treatment of musculoskeletal disorders
eliemtx.com2018Boston, United States$171.3M30
Develops antibody-based treatments for autoimmune and inflammatory disorders.
zogenix.com2006Emeryville, United States$149.06M159
Drug delivery systems for CNS disorders and pain are developed.
Premium access

Detailed competitors of Cersci Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Pain Management

3 companies that operate in the same segment as ​​Cersci Therapeutics (Pain Management) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of therapies for the treatment of musculoskeletal disorders
2007Woburn, Massachusetts, United StatesUSD 62 MUSD 85.55 M692
Developer of therapeutics for pain relief and inflammatory diseases
2004New York, New York, United StatesUSD 51 MUSD 4.33 M79
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed.
2007Philadelphia, Pennsylvania, United StatesUSD 203 MUSD 3.13 M35
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about ​​Cersci Therapeutics

Premium access

Complete news archive for Cersci Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about ​​Cersci Therapeutics

​​Cersci Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.

​​Cersci Therapeutics is headquartered in Dallas, United States. It is registered at Dallas, Texas, United States.

​​Cersci Therapeutics is a funded company, having raised a total of $12M across 4 funding rounds to date. The company's 1st funding round was a Grant of $225K, raised on Feb 2017.

Cersci Therapeutics was founded in 2015 in Dallas, United States, within the biotechnology sector. Focus is placed on non-opioid therapeutics targeting acute and chronic pain through AMPK activators and peroxynitrite scavengers. Operations involve advancing these compounds toward an Investigational New Drug application with the FDA. Technology is safeguarded by issued and pending patents, with current efforts directed toward fundraising.

​​Cersci Therapeutics's top competitors include Flexion Therapeutics, Zogenix and Eliem Therapeutics.

​​Cersci Therapeutics offers SMARThatch.

​​Cersci Therapeutics has 2 investors. Key investors include HHS, and Acadia.

​​Cersci Therapeutics operates through Cidra Concrete Systems Inc..

Yes. ​​Cersci Therapeutics was acquired by Acadia Pharma in August 2020.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available